Insight Molecular Diagnostics Faces January FDA Deadline — Missing It Would Restart Its Test Review

Management is preparing a clinical-kit launch while expanding the evidence for its kidney-transplant test and proposing a stock offering.

Share
Insight Molecular Diagnostics Faces January FDA Deadline — Missing It Would Restart Its Test Review

Insight Molecular Diagnostics, which develops molecular tests to monitor transplanted-organ rejection, must meet a January 21, 2027 FDA response deadline or restart its kidney-test application, President and CEO Josh Riggs said on Monday’s earnings call. The company is preparing to launch GraftAssureDx immediately after authorization, but first must address the agency’s concerns about its clinical evidence.

More Samples, Another Biopsy Review

The FDA’s preliminary assessment was that the clinical data submitted did not yet establish support for GraftAssureDx’s proposed use. The company’s results release described the questions as primarily concerning how its clinical validation study was designed and analyzed.

Riggs told an analyst that the original application included about 75 samples. The available sample pool has since tripled, which he expects will help answer the agency’s requests for analyses of patient subgroups. He characterized the preliminary assessment as “blanket language” asking for more information.

Biopsy diagnoses are another part of the work. Responding to an analyst from BTIG, Riggs said the FDA wanted more than assessments by local pathologists: a national reviewer and a tiebreaker were needed. Slides have been transferred into a digital database for review, and the company has secured two expert pathologists.

A separate independent study is examining the test’s accuracy and consistency. Management expects both external processes to finish before year-end, allowing it to submit the complete response before the deadline.

GraftAssureDx was submitted in March. A late-July request for additional information paused the FDA review, and management met with the agency in late September to discuss its response.

Riggs expects roughly 75 review days to remain after the company responds, although he acknowledged the FDA could take longer. Missing the response deadline “basically kills the submission,” he told BTIG, requiring resubmission and a fresh 150-day review clock. The FDA has not decided whether to authorize the test.

Small Sales Before The Kit Launch

Third-quarter revenue rose to $559,000 from approximately $260,000 a year earlier. Most came from laboratory services in Tennessee; research-use kit sales were $21,000, compared with zero in the year-earlier quarter. Gross profit was $420,000, with a 75.1% gross margin.

The business has distinct routes to customers. GraftAssureCore is tested at the company’s Franklin, Tennessee laboratory and receives Medicare reimbursement. GraftAssureIQ kits are sold for research, while GraftAssureDx is intended for clinical testing in local laboratories. Hospitals, transplant centers and laboratories are its target customers; its laboratory-services operation also serves life sciences and biotechnology companies.

Chief Financial Officer Andrea James said on Monday’s earnings call that research and development spending fell to $3.8 million in the third quarter from $5.8 million in the fourth quarter of 2025. She attributed the earlier peak to supplies, consulting and trial-site costs associated with the FDA program. Operating expenses excluding noncash items were flat against the third quarter a year earlier.

James said the company’s goal is to fund future FDA programs with gross profit from the kidney assay. For now, Insight Molecular Diagnostics has announced a proposed stock offering. Asked by an analyst from Needham why it was seeking capital now, James directed investors to the offering filing.

The GALACTIC study has begun enrolling patients at UCLA Medical Center. Riggs expects about five sites to be enrolling by year-end. Initially, participating centers send samples to the company; a later stage calls for those centers to run the tests themselves.

Ready To Manufacture, Reimbursement Comes Next

Riggs said the research-use and clinical versions differ only by “a sticker,” and that the company already manufactures the product intended for the clinical box. Centers in its FDA program have instruments on-site and have received workflow training; its beta-site program has also introduced laboratories to the technology.

Management said several hospital laboratories have completed analytical and clinical validation and are pursuing reimbursement, with some targeting service launches in 2027. A center’s field test produced a result in approximately six and a half hours, compared with the several days Riggs said send-out testing takes.

Insight Molecular Diagnostics appointed Donnie Purto senior vice president of sales on October 14, 2026, to prepare commercialization. The company’s release said the top 100 transplant centers account for about 80% of U.S. kidney transplants, supporting its plan for a focused sales team.

The initial launch will target laboratories in Medicare’s MolDX-covered jurisdictions. Riggs identified approximately 67 centers there performing more than 50 kidney transplants annually. James said the company hopes to have nationwide pricing in January 2028 and is exploring ways to obtain it sooner.

Beyond kidney testing, Riggs described urine screening for T-cell-mediated rejection and a planned expansion into heart-transplant testing. He hopes heart-study samples will support an FDA submission in the second half of 2027, while stressing that this was not formal guidance. He expects a simpler review route because an existing heart-testing device provides a comparison.

Management also targets a European submission for kidney and heart testing around year-end or early January. Riggs said the indicated review period is about six months, but limited reimbursement is constraining commercialization. James expects European reimbursement to be lower than in the United States.

The immediate hurdle is completing the independent accuracy study and biopsy review in time for January 21, 2027. The launch Riggs describes remains dependent on FDA authorization.

Sources

More on Insight Molecular Diagnostics

All Insight Molecular Diagnostics (IMDX) coverage →